Researchers develop a new method to isolate specific cells, and in the process find a more robust fluorescent protein.
A new study led by Marc Veldhoen, principal investigator at Instituto de Medicina Molecular with an interdisciplinary team of clinicians and researchers from FMUL and CHLN and collaborators at IPST, shows that 90% of subjects have detectable antibodies 40 days up to 7 months post contracting COVID-19. These results, now published in the scientific journal European Journal of Immunology, also show that age is not a confounding factor in levels of antibodies produced, but disease severity is.
Specific regions in cord blood DNA can help identify kids who might develop autism, according to a UC Davis MIND Institute study. The findings from the study may hold clues for early autism diagnosis and intervention.
New research from an immunology team at the University of Chicago may shed light on the challenges of developing a universal flu vaccine that would provide long-lasting and broad protection against influenza viruses.
A new portable "lab on a chip," developed by the U-M scientists and demonstrated with help of the CDI, can identify the presence of COVID-19 antibodies in blood donors with greater speed and efficiency than the current standard
Virologists at Institut national de la recherche scientifique (INRS) have identified a critical role played by a cellular protein in the progression of Hepatitis C virus infection, paving the way for more effective treatment. No vaccine currently exists for Hepatitis C virus infection, which affects more than 130 million people worldwide and nearly 250,000 Canadians. Antivirals exist but are expensive and not readily available in developing countries, where the disease is most prevalent.
Whole-colon imaging in mice has revealed a continuous colonic mucus system, which forms a protective barrier between potentially harmful gut microbiota and host tissue by encapsulating fecal pellets as they form and as they are eliminated from the colon.
The findings redefine how the so-called gut microbiome operates and how our bodies coexist with some of the 100 trillion bacteria that make it up. The discoveries could lead to new therapies for inflammatory bowel disease and people who've had portions of their bowels removed due to conditions like colon cancer and ulcerative colitis. They also help explain why the use of antibiotics can create a multitude of problems in the digestive system.
The study published in the journal Immunity reveals that tetracyclines (broad spectre antibiotics), by partially inhibiting cell mitochondria activity, induce a compensatory response on the organism that decreases tissue damage caused during infection. This finding opens new doors in the field of disease tolerance and positions this group of antibiotics as potential adjuvant treatment for sepsis, due to their effects that go beyond the control of bacterial burden.
A new study is the first to describe a biochemical mechanism that influences activity in a protein linked to cancer, aging, inflammatory responses and addiction-related behaviors.